Meta AnalysisID 687
外用米诺环素与甲硝唑、伊维菌素、壬二酸治疗中重度丘疹脓疱型玫瑰痤疮的疗效、安全性和耐受性比较：系统评价与Meta分析
CRD42022355230
Whether the use of topical minocycline would results in better efficacy and safety profile compared to the other topical agents (i.e., metronidazole, ivermectin, azelaic acid) for the management of moderate-to-severe pap
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 687
- Evidence Id
- 9245
- Core Evidence Id
- 9245
- Source Meta Analysis Id
- 666
- Herb2 Meta Analysis Id
- HBMA000666
- Crd Id
- CRD42022355230
- Title
- The efficacy, safety and tolerability of topical minocycline compared with metronidazole, ivermectin, azelaic acid in moderate-to-severe papulopustular rosacea: a systematic review and meta‐analysis
- Review Question
- Whether the use of topical minocycline would results in better efficacy and safety profile compared to the other topical agents (i.e., metronidazole, ivermectin, azelaic acid) for the management of moderate-to-severe papulopustular rosacea.
- Study Type Included
- Randomized controlled trials (RCTs)
- Condition Being Studied
- Papulopustular facial rosacea
- Participant
- Adult individuals aged ≥ 18 years with moderate to severe papulopustular facial rosacea defined as defined as an Investigator Global Assessment (IGA) score of 3 (moderate) or 4 (severe)
- Animal
- Human Disease Modelled
- Intervention
- Topical Minocycline foam 1% vs 1.5% vs 3% Metronidazole gel or cream 1% vs 0.75% Azelaic acid 15% vs 20% Ivermectin 1%
- Comparator Control
- Topical vehicle (placebo) or another topical agent (i.e., Metronidazole, Azelaic acid, or Ivermectin)
- Main Outcome
- proportion of patients achieving success on the IGA score (i.e., IGA 0 “clear” or 1 “almost clear”) Measures of effect Odds ratio
- Outcome Measure
- Additional Outcome
- Inflammatory lesion count, erythema severity score, Rosacea Quality of Life Index (RosaQoL) score, facial local tolerability, patient satisfaction, and adverse events Measures of effect Odds ratio will be used to represent the dichotomous outcomes: patient satisfaction, facial local tolerability, and adverse events. Mean difference (MD) will be used to represent the continuous outcomes: inflammatory lesion count, erythema severity score, Rosacea Quality of Life Index (RosaQoL) score.
- Study Method
- Intervention, Systematic review
- Keyword
- Humans; Ivermectin; Metronidazole; Minocycline; Rosacea; azelaic acid
- Contact
- Abdullah Ghaddaf [email protected]
- Organisational Affiliation
- King Saud bin Abdulaziz University for health sciences
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Saudi Arabia
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-08-22
- Registration Date
- 2022-09-02
- Anticipated Start Date
- 2022-07-01
- Anticipated Completion Date
- 2022-09-30
- Title Cn
- 外用米诺环素与甲硝唑、伊维菌素、壬二酸治疗中重度丘疹脓疱型玫瑰痤疮的疗效、安全性和耐受性比较：系统评价与Meta分析
- Title En
- The efficacy, safety and tolerability of topical minocycline compared with metronidazole, ivermectin, azelaic acid in moderate-to-severe papulopustular rosacea: a systematic review and meta‐analysis
- Bilingual Status
- complete